Skip to content

Oral drugs for dystonia in children with cerebral palsy

Comparative effectiveness of oral trihexyphenidyl versus trihexyphenidyl plus clonazepam therapy for the treatment of dystonia in children with dystonic cerebral palsy: An open label, randomized controlled trial. - CAT-DC Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026504
Enrollment
50
Registered
2020-07-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G808- Other cerebral palsy

Interventions

Intervention1: Oral Trihexyphenidyl and Clonazepam: Oral Trihexyphenidyl starting with Week 1- 0.2 mg/kg/d in 3 divided doses Week 2-0.5 mg/kg/d in 3 divided doses Week 3-1.0 mg/kg/d in 3 divided dose

Sponsors

All India Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children aged between 1-18 years 2. Diagnosed as dystonic cerebral palsy

Exclusion criteria

Exclusion criteria: Patients with one or more of following criterion will be excluded: 1. Received any other medication for dystonia in previous three months 2. Received any of the above two drugs for any other indication in previous three months 3. Presence of significant spasticity (ashworth grade 2 or more) 4. History of allergy to any of the above drugs 5. Genetic or syndromic associations 6. Severe concurrent illness or diseases not associated with cerebral palsy or unstable medical conditions like pneumonia 7. Recent orthopedic surgery/cast/botulinum toxin 8. Caregiver not providing informed consent

Design outcomes

Primary

MeasureTime frame
Difference in change in mean total BADS scores within 1 week of completing 12 weeks of intervention, between both the armsTimepoint: 12 weeks of intervention

Secondary

MeasureTime frame
Difference in change in mean total CP-QOL scores within 1 week of completing 12 weeks of intervention, between participants more then 4 years in both armsTimepoint: 12 weeks;Difference in change in mean total GMFM scores within 1 week of completing 12 weeks of intervention, between participants of 1 to 16 years of age in both armsTimepoint: 12 weeks;Difference in change in mean total QUEST scores within 1 week of completing 12 weeks of intervention, between participants of 18 months to 8 years of age in both arms.Timepoint: 12 weeks;To compare the frequency of mild, moderate, severe and life-threatening adverse effects between both armsTimepoint: 12 weeks

Countries

India

Contacts

Public ContactVetoni Moirangthem

All India Institute of Medical Sciences

sherawatdrindar@gmail.com09560182301

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026